- Home
- XPON vs GTBP Comparison
XPON vs GTBP Comparison
Compare XPON & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XPON | GTBP |
|---|---|---|
| Founded | 2016 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 8.5M |
| IPO Year | 2022 | 2016 |
Fundamental Metrics
Financial Performance| Metric | XPON | GTBP |
|---|---|---|
| Price | $0.68 | $0.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 790.0K | ★ 1.1M |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.57 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,624,939.00 | N/A |
| Revenue This Year | $61.26 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.60 | $0.40 |
| 52 Week High | $5.50 | $3.73 |
Technical Indicators
Market Signals| Indicator | XPON | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 33.29 | 33.40 |
| Support Level | $0.65 | $0.40 |
| Resistance Level | $0.98 | $0.79 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 10.11 | 8.36 |
Price Performance
Historical ComparisonAbout XPON Expion360 Inc.
Expion360 Inc is focused on the design, assembly, manufacturing, and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles (RV's) and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.